Pyxis Oncology, Inc. Contracts & Agreements
33 Contracts & Agreements
- Business Finance (9 contracts)
- Business Operations (2)
- Human Resources (9)
- Intellectual Property (7)
- Real Estate (1)
- Uncategorized (5)
- Pyxis Oncology, Inc. Deferred Compensation Plan (Filed With SEC on August 14, 2024)
- Dissolution Agreement by and among Pyxis Oncology, Inc., Alloy Therapeutics, Inc. and Voxall Therapeutics, LLC., dated February 6, 2024 (Filed With SEC on March 21, 2024)
- Amended Employment Agreement between Pyxis Oncology, Inc. and Ken Kobayashi, M.D (Filed With SEC on March 21, 2024)
- Description of registrants securities (Filed With SEC on March 21, 2024)
- Form of Registration Rights Agreement (Filed With SEC on February 28, 2024)
- Securities Purchase Agreement, dated February 26, 2024, by and among Pyxis Oncology, Inc. and each of the purchasers as party thereto (Filed With SEC on February 28, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on February 28, 2024)
- Employment Agreement between Pyxis Oncology, Inc. and Ken Kobayashi, M.D (Filed With SEC on November 28, 2023)
- Amendment No. 4 to License Agreement by and between Pyxis Oncology, Inc. and Biosion USA, Inc, dated May 17, 2023 (Filed With SEC on August 11, 2023)
- Letter Agreement by and between Pyxis Oncology, Inc. and Pfizer Inc., dated October 14, 2022 (Filed With SEC on November 1, 2022)
- Amended and Restated License Agreement by and between Pyxis Oncology, Inc. and Pfizer Inc., dated October 6, 2022 (Filed With SEC on November 1, 2022)
- License Agreement, dated March 28, 2022 between the registrant and Biosion USA, Inc (Filed With SEC on May 13, 2022)
- Description of registrants securities (Filed With SEC on March 29, 2022)
- Pyxis Oncology, Inc. Employee Stock Purchase Plan (Filed With SEC on October 4, 2021)
- Employment Agreement between Pyxis Oncology, Inc. and Ronald Herbst, Ph.D (Filed With SEC on October 4, 2021)
- Employment Agreement between Pyxis Oncology, Inc. and Jay Feingold, M.D (Filed With SEC on October 4, 2021)
- Employment Agreement between Pyxis Oncology, Inc. and Pamela Connealy (Filed With SEC on October 4, 2021)
- Pyxis Oncology, Inc. 2021 Equity Incentive Plan (Filed With SEC on October 4, 2021)
- Employment Agreement between Pyxis Oncology, Inc. and Lara Sullivan, M.D (Filed With SEC on October 4, 2021)
- Form of Indemnification Agreement (Filed With SEC on October 4, 2021)
- Form of Common Stock Certificate (Filed With SEC on October 4, 2021)
- Form of Underwriting Agreement (Filed With SEC on October 4, 2021)
- Lease by and between B9 LS Harrison & Washington LLC and Pyxis Oncology, Inc., dated September 29, 2021 (Filed With SEC on October 1, 2021)
- Collaboration Agreement by and among Pyxis Oncology, Inc., Alloy Therapeutics, Inc. and Voxall Therapeutics, LLC., dated March 30, 2021 (Filed With SEC on October 1, 2021)
- Amendment to Opt-In, Investment and Additional Consideration Agreement between Pyxis Oncology, Inc. and LegoChem Biosciences, Inc., dated August 2, 2021 (Filed With SEC on October 1, 2021)
- Pyxis Oncology, Inc. 2019 Equity Incentive Plan and related form agreements (Filed With SEC on October 1, 2021)
- Amended and Restated Investor Rights Agreement, dated March 5, 2021 (Filed With SEC on October 1, 2021)
- License Agreement by and between Pyxis Oncology, Inc. and Pfizer Inc (Filed With SEC on September 17, 2021)
- Opt-In, Investment and Additional Consideration Agreement between Pyxis Oncology, Inc. and LegoChem Biosciences, Inc (Filed With SEC on September 17, 2021)
- First Amendment to License Agreement between Pyxis Oncology, Inc. and LegoChem Biosciences Inc (Filed With SEC on September 17, 2021)
- Licensed Agreement between Pyxis Oncology, Inc. and LegoChem Biosciences Inc (Filed With SEC on September 17, 2021)
- Exclusive License Agreement between the University of Chicago and Pyxis Oncology for Cancer Immunotherapy Technology (Filed With SEC on September 17, 2021)
- Amendment No. 1 to License Agreement by and between Pyxis Oncology, Inc. and Pfizer Inc (Filed With SEC on September 17, 2021)
